原发性腹膜后脂肪肉瘤的综合治疗

The therapy of primary retroperitoneal liposarcoma

原发性腹膜后脂肪肉瘤是一种罕见的低度恶性肿瘤,约占成年人恶性肿瘤的1%.根治性切除是原发性腹膜后脂肪肉瘤最重要的治疗手段,放疗可以降低肿瘤局部复发率,图像引导的调强放射治疗（IG-IMRT）等新技术的应用降低了不良反应发生率,近年发现的一系列新型化疗药物及分子靶向药物也显示出了良好的治疗前景.目前,原发性腹膜后脂肪肉瘤需根据疾病的病理学分型和肿瘤特点等因素,采取包括手术、放疗、化疗以及分子靶向治疗在内的综合治疗.

Primary retroperitoneal liposarcoma is a rare low-grade malignant tumor and accounts for approximately 1% of all adult malignancies. Complete gross resection is the most important and maybe only method to cure retroperitoneal liposarcoma. The addition of advanced- modality radiotherapy to surgery for primary retroperitoneal liposarcoma is associated with improved local recurrence-free survival, and the toxic effect is tolerable. Several new drugs, especially targeted drugs, have achieved good efficacy. The aim of this article is to improve the understanding of treatment of primary retroperitoneal liposarcoma. The multidisciplinary therapy model, including surgery, radiotherapy, chemotherapy and targeted therapy, is recommended for patients with retroperitoneal liposarcoma.